Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Wedbush issued their FY2029 EPS estimates for shares of Xenon Pharmaceuticals in a report released on Thursday, January 23rd. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will earn $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.13) per share.
Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Raymond James reiterated an "outperform" rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, Needham & Company LLC restated a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $56.00.
Check Out Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Down 0.3 %
Shares of Xenon Pharmaceuticals stock traded down $0.11 during trading hours on Friday, hitting $39.87. The company's stock had a trading volume of 255,674 shares, compared to its average volume of 383,395. The business has a fifty day moving average of $40.23 and a 200 day moving average of $40.79. Xenon Pharmaceuticals has a 1-year low of $35.53 and a 1-year high of $50.99. The company has a market capitalization of $3.04 billion, a PE ratio of -14.15 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period last year, the firm earned ($0.73) earnings per share.
Institutional Investors Weigh In On Xenon Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of XENE. Blue Trust Inc. increased its position in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 641 shares during the period. Avior Wealth Management LLC bought a new position in Xenon Pharmaceuticals during the fourth quarter worth $101,000. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals during the 3rd quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after purchasing an additional 487 shares during the period. Finally, KBC Group NV grew its position in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.
Insiders Place Their Bets
In other news, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Gary Patou sold 4,891 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their position. The disclosure for this sale can be found here. 5.52% of the stock is owned by insiders.
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
